A Randomized, Blinded, Active-controlled Non-inferiority Study of the Efficacy and Safety of OX219 for the Induction of Treatment of Opioid Dependence

Trial Profile

A Randomized, Blinded, Active-controlled Non-inferiority Study of the Efficacy and Safety of OX219 for the Induction of Treatment of Opioid Dependence

Completed
Phase of Trial: Phase III

Latest Information Update: 16 May 2017

At a glance

  • Drugs Buprenorphine/naloxone (Primary) ; Buprenorphine
  • Indications Opioid abuse
  • Focus Registrational; Therapeutic Use
  • Sponsors Orexo
  • Most Recent Events

    • 11 Aug 2015 As per Orexo media release, the U.S. FDA has approved ZUBSOLV for induction of buprenorphine maintenance therapy (August 2015) in patients with opioid dependence.
    • 18 Mar 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 06 Dec 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top